Elite Journal of Immunology. Volume 2 issue 1(2024), Pp. 34-46
https://epjournals.com/journals/EJI

Implications of B Lymphocyte Dysfunction in HIV/AIDS

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

The ongoing battle against Human Immunodeficiency Virus (HIV) necessitates a comprehensive understanding of the intricate interplay between various components of the immune system. While the role of T lymphocytes has been extensively explored, recent research has illuminated the critical involvement of B lymphocytes and their dysfunction in the context of HIV/AIDS. This review delves into the implications of B lymphocyte dysfunction, dissecting its impact on humoral immunity, immunopathogenesis, vaccine development, and potential therapeutic interventions. In the realm of therapeutic interventions, this review evaluates current and potential strategies to rectify B lymphocyte dysfunction, ranging from immune modulatory therapies to targeted treatments aimed at restoring humoral immunity. The narrative concludes by outlining future perspectives, emphasizing the identification of biomarkers, advancements in vaccine design, and interdisciplinary collaboration as key areas of focus for further research.

Keywords*: B lymphocytes, HIV/AIDS, humoral immunity, immunopathogenesis, vaccine development, therapeutic interventions.*

Introduction

Human Immunodeficiency Virus (HIV) remains a global health challenge, affecting millions of individuals worldwide and demanding continuous scientific scrutiny. Over the decades, research has predominantly focused on the role of T lymphocytes in the immunopathogenesis of HIV/AIDS, revealing intricate details about the cellular arm of the immune response. However, recent scientific endeavors have shifted the spotlight to B lymphocytes, emphasizing their underexplored yet pivotal role in the dynamic host-virus interplay.[1-5] The immune system's

Citation: Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology, 2024; 2(1): 34-46

orchestration of defense against HIV is a complex symphony involving both cellular and humoral components.[6] While the role of T cells, particularly CD4+ T cells, in HIV infection has been extensively documented, the contribution of B cells has garnered recognition more gradually. B lymphocytes, classically known for their role in antibody production, present a critical facet of the adaptive immune response, capable of shaping the trajectory of viral infections. As our understanding of B cell biology evolves, it becomes increasingly apparent that unraveling the intricacies of B lymphocyte dysfunction is essential for comprehensively delineating the immunopathogenesis of HIV/AIDS.[7-16]

This paradigm shift prompts a reevaluation of the conventional narrative surrounding HIV pathogenesis and immunology. B lymphocytes, historically considered supportive actors in the immune response, are emerging as central figures in the ongoing battle against HIV.[17] This review aims to navigate the landscape of B lymphocyte dysfunction in the context of HIV/AIDS, scrutinizing the molecular intricacies that underscore compromised immune responses during infection. By shedding light on the multifaceted role of B cells, we hope to pave the way for innovative therapeutic interventions and contribute to the ongoing efforts to comprehensively understand and combat HIV/AIDS on a global scale.

B Lymphocyte Dysfunction in HIV/AIDS

Human Immunodeficiency Virus (HIV) infection is characterized by a complex interplay between the virus and the host immune system, with both cellular and humoral components intricately involved in the battle against the pathogen. While much attention has historically been devoted to the role of T lymphocytes, recent years have witnessed a paradigm shift, bringing to light the profound impact of B lymphocyte dysfunction on the progression of HIV/AIDS. At the heart of humoral immunity, B lymphocytes are instrumental in generating antibodies crucial for neutralizing and clearing viral infections. In the context of HIV/AIDS, these sentinel cells face a series of challenges that compromise their ability to mount an effective antibody response. The virus exhibits a remarkable ability to mutate and evade immune detection, leading to the continuous stimulation of B cells and eventual exhaustion. This chronic stimulation not only hampers the production of high-affinity antibodies but also contributes to the dysregulation of B cell function. HIV infection induces a state of chronic immune activation, placing an unprecedented burden on B lymphocytes. This perpetual state of heightened activity leads to dysregulated B cell activation, characterized by aberrant signaling pathways and altered cytokine profiles. Consequently, B cells may undergo premature exhaustion, losing their ability to effectively respond to new antigenic challenges. The dysregulation of B cell activation also fosters the expansion of B cell subsets with immunosuppressive properties, further exacerbating the immune dysfunction observed in HIV/AIDS.[18-37]

The intricate balance of B cell subsets, including memory B cells and plasma cells, is crucial for sustained and effective immune responses. In HIV/AIDS, the homeostasis of these subsets is

disrupted, leading to perturbations in the normal functioning of humoral immunity. The depletion of memory B cells, essential for mounting anamnestic responses upon re-exposure to pathogens, contributes to the compromised ability to generate immunological memory. Concurrently, the persistence of dysfunctional B cell subsets, such as exhausted B cells and regulatory B cells, skews the immune response towards a state of chronic immune dysregulation. The ramifications of B lymphocyte dysfunction reverberate through humoral immunity, impacting the production of neutralizing antibodies, antibody-dependent cellular cytotoxicity (ADCC), and the overall efficacy of antibody-mediated viral control. The impaired ability to generate broadly neutralizing antibodies against diverse HIV strains poses a significant hurdle in developing effective therapeutic interventions and preventive vaccines. Additionally, compromised ADCC diminishes the host's capacity to eliminate infected cells, further contributing to viral persistence.[38-52]

Humoral Immunity in HIV/AIDS

Humoral immunity, orchestrated by B lymphocytes and the antibodies they produce, stands as a sentinel against invading pathogens. In the context of Human Immunodeficiency Virus (HIV), humoral immunity plays a crucial role in the initial response to infection, yet its effectiveness is notably compromised over the course of the disease. Upon HIV entry into the host, B lymphocytes play a pivotal role in initiating the immune response by producing a range of antibodies. However, the virus possesses a remarkable capacity for mutation and evasion, leading to the continuous stimulation of B cells. This perpetual stimulation results in a state of chronic immune activation, ultimately contributing to the exhaustion of B cells and compromising the initial humoral response. The ability of HIV to evade neutralization by antibodies presents a formidable challenge, setting the stage for a complex interplay between the virus and humoral immunity. Neutralizing antibodies, a cornerstone of humoral immunity, are tasked with directly inhibiting the infectivity of the virus. In the context of HIV/AIDS, the generation of broadly neutralizing antibodies (bNAbs) capable of targeting diverse viral strains is a key objective for vaccine development. However, the virus's ability to rapidly mutate and evade immune detection poses a significant hurdle in the production of bNAbs. As a consequence, the humoral response is often strain-specific, allowing the virus to persist and adapt, ultimately impacting the host's ability to control the infection.[53-62]

Humoral immunity extends beyond the direct neutralization of virus particles. Antibody-Dependent Cellular Cytotoxicity (ADCC) involves the recruitment of immune cells, such as natural killer cells, by antibodies to eliminate infected cells. In the context of HIV, the effectiveness of ADCC is influenced by the specificity and functionality of antibodies.[63-64] Dysfunctional B lymphocytes and impaired antibody production observed in HIV/AIDS contribute to a compromised ADCC, diminishing the host's capacity to clear infected cells and contributing to viral persistence. The intricate dynamics between humoral immunity and HIV substantially influence disease progression. While a robust initial antibody response is mounted, the sustained stimulation of B cells and subsequent dysfunction contribute to a decline in humoral immunity over time. This decline correlates with disease progression, highlighting the intricate balance required for effective viral control. The impairment of humoral immunity, including reduced

antibody diversity and functionality, further accentuates the challenges in mounting an enduring defense against HIV.[65-74]

Immunopathogenesis and Disease Progression

The immunopathogenesis of Human Immunodeficiency Virus (HIV) infection intricately weaves together a series of events that shape the trajectory of the disease. This multifaceted journey involves a dynamic interplay between the virus and the host immune system, ultimately dictating the pace of disease progression. HIV's ability to persist within the host, even in the face of robust immune responses, stands as a hallmark of its immunopathogenesis. The virus employs various strategies to evade clearance, including the rapid mutation of its genetic material, which hinders the effectiveness of neutralizing antibodies. Additionally, the establishment of long-lived reservoirs, such as latently infected CD4+ T cells, serves as a sanctuary for the virus, allowing it to evade both the immune system and antiretroviral therapies. The persistence of HIV undermines the host's capacity for viral control and contributes significantly to the chronic nature of the infection. HIV has evolved intricate mechanisms to subvert the host's immune surveillance, exploiting the very components designed to eliminate the virus. The virus selectively targets CD4+ T cells, which are central orchestrators of the immune response, leading to their depletion and functional impairment. Furthermore, HIV employs molecular mimicry and decoy strategies to evade neutralization by antibodies. The constant adaptation of the virus to host immune pressures underscores the ongoing battle between the virus and the host's defenses, contributing to the gradual breakdown of immune function.[75-79]

The persistent presence of HIV triggers a state of chronic immune activation and inflammation, laying the groundwork for disease progression.[80] Chronic inflammation is characterized by elevated levels of proinflammatory cytokines, immune cell activation, and increased cell turnover. This sustained inflammatory milieu not only accelerates the depletion of CD4+ T cells but also contributes to the dysfunction of other immune cells, including B lymphocytes. The resultant immune dysregulation further perpetuates viral persistence, creating a self-reinforcing cycle that amplifies the impact of HIV on the immune system. Central to the immunopathogenesis of HIV/AIDS is the establishment of reservoirs that harbor latent virus, eluding both the immune response and antiretroviral therapy. Latently infected CD4+ T cells, residing in lymphoid tissues and other anatomical sanctuaries, serve as a source of ongoing viral replication once reactivated. The persistence of these reservoirs poses a significant obstacle to viral eradication and poses challenges for achieving long-term remission or a functional cure for HIV. Understanding the dynamics of reservoir establishment and maintenance is crucial for designing strategies to target and eliminate these hidden viral reservoirs. The interplay between viral persistence, immune evasion, and the establishment of reservoirs significantly influences clinical outcomes in HIV/AIDS. Disease progression is intricately linked to the extent of immune dysfunction, with lower CD4+ T cell counts correlating with increased susceptibility to opportunistic infections and AIDS-related complications. The immunopathogenic mechanisms discussed not only contribute to the progression from HIV infection to AIDS but also shape the spectrum of clinical manifestations observed in individuals living with the virus.

Implications for Vaccine Development

The development of a safe and efficacious vaccine against Human Immunodeficiency Virus (HIV) remains a paramount goal in the global battle against the virus. However, the unique challenges posed by HIV's complex immunopathogenesis and the intricacies of the host-virus interplay underscore the need for innovative approaches in vaccine design. HIV's remarkable genetic diversity and its capacity for rapid mutation pose formidable challenges in generating a vaccine capable of inducing broadly neutralizing antibodies (bNAbs) against a spectrum of viral strains.[81] The constant evolution of viral epitopes and the evasion strategies employed by the virus complicate the development of a one-size-fits-all vaccine. Overcoming this hurdle necessitates innovative vaccine formulations that can elicit a robust and durable bNAb response, targeting conserved regions of the virus and fostering cross-reactivity. Understanding the nuances of the immune response in natural HIV controllers—individuals who control the virus without antiretroviral therapy—offers valuable insights for vaccine development. These individuals often exhibit distinct immune profiles, including the spontaneous generation of bNAbs. Vaccine strategies that mimic and enhance these naturally occurring immune responses, such as the design of immunogens that replicate key viral epitopes, hold promise in eliciting a more effective and durable protective response.

Given the pivotal role of B lymphocytes in the humoral response against HIV, addressing B cell dysfunction becomes paramount in vaccine development. Novel vaccine formulations may need to consider strategies to restore B cell function, counteract chronic immune activation, and promote the generation of high-affinity antibodies. Tailoring vaccines to mitigate the impact of B lymphocyte exhaustion and dysregulation could enhance the efficacy of humoral immunity in preventing HIV infection. Harnessing the potential of immune modulation offers a promising avenue to enhance vaccine responses against HIV. Strategies involving adjuvants, immunomodulators, and cytokine therapies can be explored to fine-tune the host immune response, promoting the generation of potent and sustained immunity. The careful modulation of immune pathways, including those influencing B and T lymphocytes, could optimize vaccine-induced protective responses.[82] Recognizing the heterogeneity in immune responses among individuals living with HIV, personalized vaccine approaches tailored to individual immune profiles are gaining attention. Heterologous prime-boost strategies, involving the sequential administration of different vaccine components, aim to optimize immune responses. By carefully selecting immunogens and adjuvants based on individual immune characteristics, these approaches seek to enhance the breadth and depth of vaccine-induced protection.

Conclusion

In the ever-evolving landscape of HIV/AIDS research, our journey through the implications of B lymphocyte dysfunction, humoral immunity, immunopathogenesis, and vaccine development sheds light on both the challenges and promising avenues that shape the battle against this formidable virus. The intricate interplay between HIV and the immune system, particularly the central role of B lymphocytes, underscores the need for a holistic understanding of the

immunological dynamics at play. B lymphocyte dysfunction emerges as a critical player in the immunopathogenesis of HIV/AIDS, influencing humoral immunity, antibody responses, and overall immune function. This exploration reveals the multifaceted challenges posed by chronic immune activation, impaired antibody production, and the establishment of viral reservoirs. Understanding these complexities lays the foundation for targeted therapeutic interventions aimed at restoring B cell function and, in turn, bolstering the host's ability to mount an effective immune response against HIV.

Humoral immunity, characterized by the production of antibodies, emerges as a double-edged sword in the context of HIV/AIDS. While B cells play a crucial role in initiating immune responses, their dysfunction and the virus's ability to evade neutralization pose significant hurdles. The delicate balance between the host's immune defenses and the virus's adaptive strategies underscores the intricacies of developing an effective vaccine. The quest for a vaccine against HIV demands innovative strategies, from eliciting broadly neutralizing antibodies to mimicking natural immune responses and addressing B lymphocyte dysfunction.

References

1. Johnson AM. Pandemic HIV and its legacy for medicine and global health. Clinical Medicine. 2023.
2. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
3. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
4. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
5. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
6. Wu RQ, Zhang DF, Tu E, Chen QM, Chen W. The mucosal immune system in the oral cavity—an orchestra of T cell diversity. International journal of oral science. 2014;6(3):125-132.
7. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
8. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.

Citation: Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology, 2024; 2(1): 34-46

9. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
10. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
11. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
12. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
15. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
16. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
17. Kazer SW, Walker BD, Shalek AK. Evolution and diversity of immune responses during acute HIV infection. Immunity. 2020;53(5):908-924.
18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf

20. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
22. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
23. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
24. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
25. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
26. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
27. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
28. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.

29. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
30. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
31. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
32. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
33. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
34. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
35. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
36. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
37. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-

Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.

38. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
39. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
40. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
41. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
42. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
43. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
44. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
45. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
46. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
47. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci.

2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.

48. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
49. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
50. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
51. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
52. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
53. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
54. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
55. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
56. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
57. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.

58. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
59. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
60. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
61. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
62. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
63. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, Komoriya A, Ochsenbauer C, Kappes JC, Roederer M, Huang Y. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry Part A. 2011;79(8):603-612.
64. Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, Abdool Karim S, Moore PL, Ackerman ME, Alter G, Morris L. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS pathogens. 2018;14(4):e1006987.
65. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
66. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
67. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
68. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
69. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
70. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.

71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
72. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
73. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
74. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
75. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
76. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
77. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
78. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
79. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
80. Colomb F, Giron LB, Trbojevic-Akmacic I, Lauc G, Abdel-Mohsen M. Breaking the glyco-code of HIV persistence and immunopathogenesis. Current HIV/AIDS Reports. 2019; 16:151-168.
81. Verkoczy L, Alt FW, Tian M. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunological reviews. 2017;275(1):89-107.
82. Schijns V, Fernández-Tejada A, Barjaktarović Ž, Bouzalas I, Brimnes J, Chernysh S, Gizurarson S, Gursel I, Jakopin Ž, Lawrenz M, Nativi C. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological reviews. 2020;296(1):169-190.